The estimated Net Worth of Andrew R Neill is at least $2.49 millió dollars as of 10 January 2024. Mr Neill owns over 25,000 units of Shattuck Labs stock worth over $646,954 and over the last 4 years he sold STTK stock worth over $1,839,620.
Mr has made over 11 trades of the Shattuck Labs stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 25,000 units of STTK stock worth $250,000 on 10 January 2024.
The largest trade he's ever made was selling 25,000 units of Shattuck Labs stock on 10 January 2024 worth over $250,000. On average, Mr trades about 8,669 units every 89 days since 2020. As of 10 January 2024 he still owns at least 173,446 units of Shattuck Labs stock.
You can see the complete history of Mr Neill stock trades at the bottom of the page.
Andrew R. Neill M.B.A. is the VP of Fin. & Corp. Strategy at Shattuck Labs.
Mr A is 35, he's been the VP of Fin. & Corp. Strategy of Shattuck Labs since . There are 7 older and no younger executives at Shattuck Labs. The oldest executive at Shattuck Labs, Inc. is Dr. Arundathy Nirmalini Pandite M.B.A., M.D., 62, who is the Chief Medical Officer.
Andrew's mailing address filed with the SEC is C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN, TX, 78701.
Over the last 4 years, insiders at Shattuck Labs have traded over $14,634,250 worth of Shattuck Labs stock and bought 3,526,605 units worth $60,008,520 . The most active insiders traders include Group, Llc Green Jeremy Red..., Clay B Siegall és Josiah Hornblower. On average, Shattuck Labs executives and independent directors trade stock every 25 days with the average trade being worth of $300,381. The most recent stock trade was executed by Tyler Brous on 27 June 2024, trading 8,416 units of STTK stock currently worth $32,738.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs executives and other stock owners filed with the SEC include: